32 results about "Targeted immunotherapy" patented technology

The invention provides an immunotherapy reaction marker identification method and system based on a cooperative game theory, and relates to the technical field of intelligent medical treatment, and the method comprises the following steps: obtaining immunotherapy single cell sequencing data, and determining a candidate gene set through differential expression analysis; extracting regulation and control relation pairs of the candidate gene set to obtain a multi-level information gene regulation and control network; embedding the multilevel information gene regulation and control network by adopting a Node2vec algorithm to obtain a network module containing potential biological functions, calculating the contribution degree of each gene feature to model prediction based on a Myerson value, and obtaining a feature importance sequence; combining the optimal features of the modules into a global candidate set; and iteratively optimizing the global candidate set, and outputting a target immunotherapy reaction marker set. Through a Myerson value principle in a cooperative game, a biomarker set related to immunotherapy response is efficiently searched, deep analysis of a drug resistance mechanism is realized, the accuracy and robustness of marker screening are improved, and the method serves for cancer clinical scheme customization.

The invention discloses a PD-1 (programmed death-1) and PD-L1 (programmed death-L1) gene polymorphism detection kit and a use method thereof. The kit is used for detecting an rs34819629 site of a PD-1 gene and an rs2297137 site of a PD-L1 gene, four groups of primer sequences are designed, and the kit further comprises a PCR (Polymerase Chain Reaction) reaction buffer solution, dNTPs (Deoxyribose Nucleic Acid), DNA (Deoxyribonucleic Acid) polymerase and template DNA. The kit disclosed by the invention is an efficient tool for detecting the specific polymorphism of the PD-1 and PD-L1 genes, and has the characteristics of high accuracy, simplicity in operation and capability of supporting personalized medical treatment. Through the detection kit, targeted immunotherapy suggestions can be provided for patients, the effectiveness of immunotherapy is remarkably improved, important gene information is provided for related researches, and development of diabetes immunotherapy is promoted.

To provide improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.SOLUTION: Provided are VHH-based dimerizing agent regulated immunoreceptor complexes (DARICs) and VHH-based chimeric antigen receptors (CARs) directed against CLL-1, polynucleotides encoding the same, compositions thereof, and methods of making and using the same to treat cancer.SELECTED DRAWING: Figure 1A

The invention provides an application of an ANXA1 protein or an antagonist thereof in preparation of a medicine for treating multiple myeloma. After the multiple myeloma BCMA immunotherapy, when BCMA negative recurrence occurs, in multiple myeloma cells, a BCMA receptor signal channel is reduced, ANXA1 protein expression quantity is increased, proliferation of the multiple myeloma cells is promoted, and CAR-T cell immunocompetence and immune persistence are inhibited at the same time. The antagonist of the ANXA1 protein reduces the expression quantity of the ANXA1 protein, inhibits the proliferation of multiple myeloma cells, and recovers the immunocompetence and immune persistence of CAR-T cells at the same time. According to the application, the biological function of the ANXA1 in the MM cells is defined, the action mechanism of the ANXA1 antagonist for treating the BCMA negative MM cells and improving the activity of the CAR-T cells is proved, a valuable theoretical basis is provided for improvement of clinical myeloma CAR-T cell treatment, and finally the disease-free lifetime of a patient after BCMA-targeted immunotherapy is prolonged.

Methods and compounds for conferring kidney-glomerular-specific immunotherapy.

Provided herein are compositions, systems, and methods for producing small extracellular vesicles (sEVs) that are mRNA-loaded and include CD64 on the sEV surface. Also provided are the immunogenic EVs (imsEVs) that further include a targeting ligand bound to the CD64 on the imsEV surface. The disclosure also provides fusion proteins including a CD64 amino acid sequence fused to an N peptide amino acid sequence. Also provided are nucleic acids that encode the fusion proteins, and vectors and cells that comprise the nucleic acids. Also disclosed are methods for using the imsEVs for immunotherapy, such as for the treatment of cancer in a subject.

The invention discloses a prediction model for predicting a liver cancer combined treatment effect based on multi-mode MRI radiomics characteristics and a construction method and application thereof, and belongs to the technical field of liver cancer treatment effect prediction. In order to solve the problem that only part of liver cancer patients can benefit from an arterial chemoembolization combined targeted immunotherapy scheme at present, the invention proposes that before combined therapy, MRI radiomics characteristics and clinical factors are enhanced through noninvasive multi-modal comparison, multiple machine learning models are established, and the model learning model is used for learning the liver cancer patients. The tumor treatment response of arterial chemoembolism combined with molecular targeting and immunotherapy is predicted, and the applicability of the radiomics model is verified by using an external data set; besides, the radiomics model is combined with a clinical model, so that the method has more excellent prediction efficiency, and the radiomics features provide incremental prediction value for clinical factors. According to the method, the combined treatment effect of the liver cancer patients can be predicted, so that more effective and reasonable treatment schemes can be selected for different patients before treatment.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Provided are novel human-derived antibodies specific for transthyrelin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CD1a-targeting moieties comprising a CD1a-which may be placed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapy for treating, preventing or ameliorating at least one symptom or a condition associated therewith of cancer, infectious diseases, autoimmune diseases, inflammatory diseases and immune deficiencies.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

Provided are novel human-derived antibodies specific for transthyrelin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

The invention provides application of luteolin in enhancement of lung cancer targeted immunotherapy, relates to the technical field of biological medicine, and relates to combined application of traditional Chinese medicine monomer luteolin and an immunotherapy preparation of a targeted immune checkpoint B7-H3 in treatment of non-small cell lung cancer (NSCLC). The immunotherapeutic agent is preferably a bispecific killer cell adapter (BiKE) that targets both B7-H3 and CD16. In-vitro cell experiments and in-vivo animal models prove that luteolin can significantly enhance the killing effect of the B7-H3 targeted immunotherapy on NSCLC cells, and the luteolin and the B7-H3 targeted immunotherapy show a significant synergistic anti-tumor effect. The action mechanism of the luteolin is possibly related to the luteolin for inducing cell apoptosis, improving the level of reactive oxygen species (ROS) in cells and inhibiting a PI3K / AKT signal channel. The combined strategy provides a new effective scheme for solving the problems of limited curative effect and drug resistance of NSCLC immunotherapy, and has a good clinical application prospect.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.

This invention provides a BiTE for targeted immunotherapy of tumors, its preparation method, and its application, relating to the field of biopharmaceutical technology. The BiTE is obtained by conjugating a nanobody to a fusion protein. The nanobody contains the amino acid sequence SEQ ID No. 3 at its C-terminus and has the function of targeting the human epidermal growth factor receptor on tumor cells. The fusion protein also targets the CD3 receptor on T cells and activates T cells, connecting T cells and tumor cells in time and space, activating T cells to secrete perforin and granzyme B to kill tumor cells, thus exerting a targeted immunotherapy effect. This invention utilizes isopeptide bonds to conjugate the nanobody and the fusion protein, completing the conjugation within 15 minutes with a conjugation efficiency of 100%, and extending the in vivo half-life of the nanobody by 6 times.

The present disclosure provides improved CD33-targeting polypeptides and compositions for adoptive T cell therapy for treating, preventing, or ameliorating at least one symptom of, or a condition associated with, cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immunodeficiency.

The invention discloses a curative effect prediction method for a hepatocellular carcinoma patient receiving TACE combined target immunotherapy, and relates to the field of medical data processing, and the method comprises the steps: inputting energy spectrum CT data and perfusion CT data into a first deep learning model, predicting a first curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the first deep learning model; inputting the image data into a second deep learning model, and predicting a second curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the second deep learning model; inputting the clinical examination data into a third deep learning model, and predicting a third curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the third deep learning model; and performing cross-modal fusion on the first curative effect prediction result, the second curative effect prediction result and the third curative effect prediction result to obtain a target curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy.

The invention belongs to the technical field of biotechnology and immunology, and particularly relates to application of MTAP as a tumor immunosuppression state and prognosis marker and as a tumor immunotherapy target. The invention reveals that MTAP does not have a'cancer inhibition 'function in TAMs for the first time, but promotes immune escape by inhibiting ferroptosis, breaks through the traditional cognition on the MTAP function, provides a scientific basis for developing a tumor prognosis detection method based on MTAP, an immunosuppressive cell transformation strategy and a novel TAMs-targeted immunotherapy strategy, and has a wide application prospect. A new path is provided for improving the solid tumor immunotherapy curative effect and overcoming drug resistance. The invention also provides an application of the MTAP as a marker in preparation of a detection reagent for predicting the immunosuppression state or clinical prognosis of a tumor patient and an application of the MTAP as an immunotherapy target in preparation of a tumor immunotherapy drug, so that a new thought is provided for tumor detection and immunotherapy.

The present invention discloses a two-dimensional black phosphorus hybrid nanomedicine modified by RC48 protein, and its preparation method and application. The medicine uses a metabolizable two-dimensional black phosphorus quantum sheet as an inorganic carrier, and is modified by methoxypolyethylene glycol monoamine to improve the colloidal stability and biocompatibility, and enhance the antigen capture ability of antigen-presenting cells. Further conjugated with vedicitumumab to achieve active targeting of HER2-positive tumors, and at the same time loaded with adjuvant resiquimod to activate immune cells and induce macrophages to secrete M1-type cytokines to reverse tumor immunosuppression. This system realizes precise treatment through a "target recognition-photothermal ablation-immune activation" synergistic mechanism. Its innovation lies in the first integration of RC48 and R848 on a photosensitive black phosphorus platform, which significantly enhances the ability to regulate the tumor microenvironment while ensuring mild reaction conditions, providing a new strategy for targeted immunotherapy of breast cancer.

The present invention provides a method for detecting transient and stable transfection of autoimmunity encephalitis antibodies and its application. Specifically, the present invention provides a recombinant cell expressing mutant NMDAR, wherein the recombinant cell expresses a fusion protein of exogenous mutant NMDAR and a fluorescent protein, and has a high transfection survival rate. The recombinant cell of the present invention can be used to detect antibodies related to autoimmunity encephalitis, including NMDAR, AMPAR1, AMPAR2, LGI1, Caspr2, GABA B R. The present invention also provides a recombinant transfected cell line based on the present invention, and uses the transfected cell line to detect the method for anti-autoimmunity encephalitis by indirect immunofluorescence method. The method of the present invention has high sensitivity and specificity, and can accurately detect the types of pathogenic antibodies, so as to help patients implement targeted immunotherapy and recover health.

Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.

The invention provides a biological marker for kidney cancer with vein cancer thrombus and application of the biological marker, and relates to the technical field of bioinformatics. The biological marker for the kidney cancer with the vein cancer thrombus comprises serum amyloid protein A. The biomarker disclosed by the invention can improve the treatment effect: by revealing the action mechanism of SAA in kidney cancer embolus treatment, a basis is provided for optimizing a new auxiliary target-immunization combined treatment scheme, and the treatment effect is improved. The biomarker provided by the invention can reduce treatment drug resistance: by regulating SAA and related signal channels thereof, the sensitivity of tumor cells to target immunotherapy can be possibly enhanced, and occurrence of drug resistance is reduced. The clinical application value of the biomarker is as follows: a new biomarker and a treatment target are provided for clinical treatment of patients with kidney cancer thrombus, and the biomarker has important clinical application value. The SAA detection can be used as an important index for evaluating the treatment effect and predicting the drug resistance, and is used for guiding clinical treatment decisions and improving the treatment effect and life quality of patients.

The present invention relates to the field of biomedical technologies, and specifically discloses the application of CCR5<supgt;hi< / supgt> innate immune memory cells in the preparation of immunotherapeutic drugs for the treatment of sepsis. The present invention provides an innate immune memory cell, CD45<supgt;+< / supgt>CD11b<supgt;+< / supgt>Ly6G<supgt;‑< / supgt>Ly6C<supgt;+< / supgt>CCR5<supgt;hi< / supgt> monocytes, which is induced by BCG combined with bacterial lipoprotein to train immunity and has a protective effect on sepsis. Through single-cell sequencing analysis and functional verification, the cell subset characteristics are accurately identified, and its functional mechanism is clarified, thereby filling the key gaps of "unclear effector cell identity and unclear action targets" in the existing technology, providing a theoretical basis and technical solution at the cellular level for the targeted immunotherapy of sepsis, and is expected to achieve better therapeutic effects in clinical practice.